Menu
Recruiting NCT04597437

Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)

Phase II Interventional Dengue Fever

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Zanamivir, Placebo.
Who it may be relevant to
Registry conditions: Dengue Fever. Basic parameters: from 7 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Colombia
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE): A Pilot Randomized Controlled Trial

Overview

ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability syndrome which is the main cause of death in dengue fever.

Detailed description

ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability syndrome which is the main cause of death in dengue fever. Our central hypothesis is that zanamivir treatment is safe in patients with dengue infection, will significantly decrease serum sialic acid levels, and will result in fewer patients with the development of moderate or severe clinical plasma leakage. 74 male and non-pregnant female volunteers age 7 years and older from Colombia with a diagnosis of dengue fever with warning signs or severe dengue as per the World Health Organization 2009 definition with the presence of fever and positive rapid test for the presence of dengue non-structural protein-1 (NS1) will be randomized to zanamivir versus placebo. In the treatment group, all participants weighing less than 50 kg will receive 12 mg/kg and all participants weighing 50 kg and above will receive 600 mg as the initial dose intravenously every twelve hours for 5 days adjusted for renal function. In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.

All patients will receive blood draws for assessment of hematocrit, renal function, and biologic efficacy endpoints and clinical evaluation of signs and symptoms of vascular permeability (which may include ultrasound and radiograph) and adverse events daily during the five days of medication administration and once at follow up at 14 days.

Interventions

  • Drug Zanamivir
    Intravenous zanamivir
  • Other Placebo
    In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.

Primary outcome measures

  • Incidence of Treatment-Emergent Adverse Events of intravenous zanamivir treatment versus placebo in dengue [Time frame: Over 14 days]
Secondary outcome measures (2)
  • Levels of endothelial glycocalyx biomarkers in intravenous zanamivir treatment versus placebo in dengue [Time frame: Over 14 days]
  • Preliminary clinical efficacy of intravenous zanamivir treatment versus placebo in dengue [Time frame: Over 14 days]

Eligibility criteria

Inclusion criteria

  • Provision of signed and dated informed consent form.
  • Stated willingness to comply with all study procedures and availability for the duration of the study.
  • Male or female, aged >7 years
  • Willingness to receive intravenous medication and be willing to adhere to the medication regimen
  • Have a diagnosis of dengue by dengue NS1 rapid test
  • Have had a self-informed fever >38 degrees C in the last 3 days.
  • Have dengue with warning signs as per the 2009 WHO criteria including one of the following: abdominal pain or tenderness, persistent vomiting, clinical fluid accumulation, mucosal bleeding, lethargy, restlessness, liver enlargement over 2 cm, augmented hematocrit, thrombocytopenia or severe dengue defined as dengue with severe plasma leakage leading to dengue shock and/or fluid accumulation with respiratory distress; severe hemorrhage; severe organ impairment (hepatic damage, renal impairment, cardiomyopathy, encephalopathy or encephalitis).
  • Enrollment in EPS (Entidadas Promotoras de Salud) or Sistema General de Seguridad Social en Salud (SGSSS)- Colombian Public Health Insurance.

Exclusion criteria

  • Pregnancy or lactation
  • Children in Care of the state
  • Patients who are unlikely to survive 48 hours
  • Unstable cardiac disease or arrhythmia at baseline
  • History of significant cardiac disease
  • Treatment with another investigational drug or other intervention within 1 month.
  • Encephalitis or unable to consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

Colombia · 2 centers
  • Cien Salud IPS SAS — Barranquilla
  • Clinica de la Costa SAS — Barranquilla

Identifiers

NCT: NCT04597437 · NCR203024

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗